Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/62888
Type
ArticleCopyright
Restricted access
Embargo date
2030-12-31
Collections
- INI - Artigos de Periódicos [3495]
Metadata
Show full item record
CAN CURCUMIN SUPPLEMENTATION BREAK THE VICIOUS CYCLE OF INFLAMMATION, OXIDATIVE STRESS, AND UREMIA IN PATIENTS UNDERGOING PERITONEAL DIALYSIS?
Author
Affilliation
Federal University of Rio de Janeiro. Division of Nephrology. Rio de Janeiro, RJ, Brazil.
Federal University of Rio de Janeiro. Graduate Program in Biological Sciences - Physiology. Rio de Janeiro, RJ, Brazil / Fluminense Federal University. Graduate Program in Nutrition Sciences. Niterói, RJ, Brazil.
Fluminense Federal University. Graduate Program in Nutrition Sciences. Niterói, RJ, Brazil / Fluminense Federal University. Graduate Program in Cardiovascular Sciences. Niterói, RJ, Brazil.
Fluminense Federal University. Graduate Program in Medical Sciences. Niterói, RJ, Brazil.
Fluminense Federal University. Graduate Program in Cardiovascular Sciences. Niterói, RJ, Brazil.
Fluminense Federal University. Graduate Program in Cardiovascular Sciences. Niterói, RJ, Brazil.
Oswaldo Cruz Foundation. Evandro Chagas National Institute of Infectology. STD and AIDS Clinical Research Laboratory. Rio de Janeiro, RJ, Brazil.
Federal University of Rio de Janeiro. Graduate Program in Biological Sciences - Physiology. Rio de Janeiro, RJ, Brazil / Federal University of Rio de Janeiro. Institut of Biophysics Carlos Chagas Filho. Rio de Janeiro, RJ, Brazil.
Federal University of Rio de Janeiro. Institut of Biophysics Carlos Chagas Filho. Rio de Janeiro, RJ, Brazil.
Federal University of Paraná. Department of Basic Pathology. Curitiba, PR, Brazil.
Federal University of Paraná. Department of Basic Pathology. Curitiba, PR, Brazil.
Apis Flora Indl. Coml. Ltda. Development, And Innovation Department. Research. Ribeirão Preto, SP, Brazil.
Federal University of Rio de Janeiro. Division of Nephrology. Rio de Janeiro, RJ, Brazil.
Federal University of Rio de Janeiro. Graduate Program in Biological Sciences - Physiology. Rio de Janeiro, RJ, Brazil / Fluminense Federal University. Graduate Program in Nutrition Sciences. Niterói, RJ, Brazil / Fluminense Federal University. Graduate Program in Medical Sciences. Niterói, RJ, Brazil.
Federal University of Rio de Janeiro. Graduate Program in Biological Sciences - Physiology. Rio de Janeiro, RJ, Brazil / Fluminense Federal University. Graduate Program in Nutrition Sciences. Niterói, RJ, Brazil.
Fluminense Federal University. Graduate Program in Nutrition Sciences. Niterói, RJ, Brazil / Fluminense Federal University. Graduate Program in Cardiovascular Sciences. Niterói, RJ, Brazil.
Fluminense Federal University. Graduate Program in Medical Sciences. Niterói, RJ, Brazil.
Fluminense Federal University. Graduate Program in Cardiovascular Sciences. Niterói, RJ, Brazil.
Fluminense Federal University. Graduate Program in Cardiovascular Sciences. Niterói, RJ, Brazil.
Oswaldo Cruz Foundation. Evandro Chagas National Institute of Infectology. STD and AIDS Clinical Research Laboratory. Rio de Janeiro, RJ, Brazil.
Federal University of Rio de Janeiro. Graduate Program in Biological Sciences - Physiology. Rio de Janeiro, RJ, Brazil / Federal University of Rio de Janeiro. Institut of Biophysics Carlos Chagas Filho. Rio de Janeiro, RJ, Brazil.
Federal University of Rio de Janeiro. Institut of Biophysics Carlos Chagas Filho. Rio de Janeiro, RJ, Brazil.
Federal University of Paraná. Department of Basic Pathology. Curitiba, PR, Brazil.
Federal University of Paraná. Department of Basic Pathology. Curitiba, PR, Brazil.
Apis Flora Indl. Coml. Ltda. Development, And Innovation Department. Research. Ribeirão Preto, SP, Brazil.
Federal University of Rio de Janeiro. Division of Nephrology. Rio de Janeiro, RJ, Brazil.
Federal University of Rio de Janeiro. Graduate Program in Biological Sciences - Physiology. Rio de Janeiro, RJ, Brazil / Fluminense Federal University. Graduate Program in Nutrition Sciences. Niterói, RJ, Brazil / Fluminense Federal University. Graduate Program in Medical Sciences. Niterói, RJ, Brazil.
Abstract
Background & aims: Turmeric (a source of curcumin) is an excellent food to modulate oxidative stress, inflammation, and gut dysbiosis in patients with chronic kidney disease (CKD). However, no studies report the benefits of curcumin in patients undergoing peritoneal dialysis (PD). This study aims to evaluate the effects of curcuminoid supplementation on oxidative stress, inflammatory markers, and uremic toxins originating from gut microbiota in patients with CKD undergoing PD. Methods: This longitudinal, randomized, single-blind, placebo-controlled trial evaluated 48 patients who were randomized into two groups: Curcumin (three capsules of 500 mg of Curcuma longa extract, with 98.42 % total curcuminoids) or placebo (three capsules of 500 mg of starch) for twelve weeks. In the peripheral blood mononuclear cells (PBMCs), the transcriptional expression levels of Nrf2, HOX-1 and NF-κB were evaluated by quantitative real-time PCR. Oxidative stress was evaluated by malondialdehyde (MDA) and total Thiol (T-SH). TNF-α and IL-6 plasma levels were measured by ELISA. P-cresyl sulphate plasma level, a uremic toxin, was evaluated by high-performance liquid chromatography (HPLC) with fluorescent detection. Results: Twenty-four patients finished the study: 10 in the curcumin group (57.5 ± 11.6 years) and 14 in the placebo group (56.5 ± 10.0 years). The plasma levels of MDA were reduced after 12 weeks in the curcumin group (p = 0.01), while the placebo group remained unchanged. However, regarding the difference between the groups at the endpoint, no change was observed in MDA. Still, there was a trend to reduce the p-CS plasma levels in the curcumin group compared to the placebo group (p = 0.07). Likewise, the concentrations of protein thiols, mRNA expression of Nrf2, HOX-1, NF-κB, and cytokines plasma levels did not show significant changes. Conclusion: Curcuminoid supplementation for twelve weeks attenuates lipid peroxidation and might reduce uremic toxin in patients with CKD undergoing PD. This study was registered on Clinicaltrials.gov as NCT04413266.
Share